Loading
Globus Medical Inc Stock: price and insider trades · United States
Globus Medical Inc: what insiders have been doing
Globus Medical Inc, founded in 2003, is a Healthcare & Pharma company based in Audubon, United States. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 11 insiders published 23 filings.
No insider bought on the market over the period, while 5 insiders filed 6 sales totalling €6.6M. Tobin James R filed the largest sale, €1.9M, on 16 September 2026, which represents 0.022% of the company's market value.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,814 companies, median 19 filings), a count of 23 filings is above the norm. Looking back to 2016, when coverage begins, insiders filed no purchases and 18 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 2.94 bn USD and net income at 537.9 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
77
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€15M
18 ops. · all time
Who traded when
BuySaleAnn D. Rhoads3 sales
David D. Davidar2 sales
Leslie Norwalk V2 sales
James R. Tobin1 sale
Stephen T. Zarrilli1 sale
Analyst consensus: bullish or bearish?
Analysts rate Globus Medical Inc Buy (bullish), based on 13 analysts. Average price target: US$100.92.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,457 of 24,148 companies
70.4
score / 100
Value59
Quality82
FCF yld5.6%
Earn yld5.2%
EV/EBITDA12.8x
ROE12%
Gross mgn67%
Net mgn18%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$76.31
Analyst consensus
13 analystsBuy
US$84.00Target US$100.92(+32%)US$125.00
Income statement
RevenueUS$2.9B
Gross profitUS$2B67% margin
EBITDAUS$814M28% margin
Net incomeUS$537.9M17.0% margin
Valuation
PER (trailing)19.6x
PER (forward)14.1x
P/Book2.1x
Beta0.96
Balance sheet & cash
Market capUS$10.2B
Total debtUS$118.7M
Free Cash FlowUS$579M
Debt / Equity2%
Profitability & ownership
ROE11.8%
ROA8.7%
% insiders0.6%
% institutions92.5%
Last declaration on 16 September 2026
Declarations77 total
15,000 shares@ US$53.750.0080% mcap10.4% of flowClass A Common StockSEC:0001193125-26-393147:0
15,000 shares@ US$63.680.0095% mcap12.4% of flowClass A Common StockSEC:0001193125-26-393147:1
30,000 shares@ US$74.58340.022% mcap29.0% of flowClass A Common StockSEC:0001193125-26-393147:2
30,000 shares@ US$74.53330.022% mcap28.9% of flowCommonSEC144:0001974078-26-000355
25,000 shares@ US$53.270.013% mcap19.6% of flowClass A Common StockSEC:0001193125-26-357121:0
25,000 shares@ US$87.03860.022% mcap32.0% of flowClass A Common StockSEC:0001193125-26-357121:1
25,000 shares@ US$87.040.022% mcap32.0% of flowCommonSEC144:0001974078-26-000312
2,500 shares0Class A Common StockSEC:0001193125-26-321442:0
25,000 shares@ US$26.270.0052% mcap4.8% of flowClass A Common StockSEC:0001193125-26-263997:0
25,000 shares@ US$80.76290.016% mcap14.7% of flowClass A Common StockSEC:0001193125-26-263997:1
25,000 shares@ US$81.000.018% mcap14.8% of flowCommonSEC144:0001974078-26-000224
20,000 shares@ US$43.5838.2% of flowClass A Common StockSEC:0001193125-26-083348:0
10,000 shares@ US$45.6419.8% of flowClass A Common StockSEC:0001193125-26-055137:0
3,594 shares@ US$51.8748.9% of flowClass A Common StockSEC:0001193125-26-010699:0
2,000 shares@ US$101.1016.6% of flowClass A Common StockSEC:0001193125-26-010697:0
6,100 shares0Class A Common StockSEC:0001193125-26-002966:0
4,000 shares@ US$88.8528.9% of flowClass A Common StockSEC:0001193125-25-320898:0
34,375 shares@ US$25.5255.8% of flowClass A Common StockSEC:0001193125-25-314329:0
3,646 shares@ US$53.1451.1% of flowClass A Common StockSEC:0001193125-25-307215:0
7,500 shares@ US$25.968.7% of flowClass A Common StockSEC:0001193125-25-302649:0
25,000 shares@ US$25.524.7% of flowClass A Common StockSEC:0001193125-25-280500:0
25,000 shares@ US$44.1416.3% of flowClass A Common StockSEC:0001193125-25-280472:0
8,000 shares@ US$81.0027.5% of flowClass A Common StockSEC:0001193125-25-274288:0
10,000 shares@ US$58.4624.4% of flowClass A Common StockSEC:0001193125-25-205135:0
7,500 shares@ US$78.6827.8% of flowClass A Common StockSEC:0000950170-25-032220:0
25 of 77 declarations
About Globus Medical Inc
Globus Medical Inc. (NYSE: GMED) is a United States-listed medical technology company traded on the NYSE and headquartered in Audubon, Pennsylvania, United States. Founded in 2003, the company has built its business around musculoskeletal solutions, with an especially strong franchise in spine, and a broader presence in orthopedic trauma, joint reconstruction, regenerative biomaterials, and enabling technologies. Its model combines product design, manufacturing, commercialization, and clinical support, giving it a vertically integrated platform that is intended to serve surgeons and hospitals with procedure-based solutions rather than isolated products. ([investors.globusmedical.com](https://investors.globusmedical.com/?utm_source=openai))
From an equity analyst perspective, GMED is positioned in a structurally attractive market. Demand is supported by aging populations, the prevalence of spinal disorders, and the ongoing shift toward more efficient, less invasive procedures. Globus differentiates itself through a sustained innovation culture, a broad procedural portfolio, and a high-touch commercial model that aims to maintain close relationships with surgeons and care teams. The company describes itself as a single operating platform, which helps align research, development, manufacturing, education, and sales around unmet clinical needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000156276225000026/gmed-20241231x10k.htm?utm_source=openai))
Read moreShow less
The company’s roots are in spine, where it initially established its brand and technical credibility, before expanding into adjacent musculoskeletal categories. In recent years, its strategic profile has become more ambitious through major transactions, most notably the NuVasive acquisition and the completion of the Nevro acquisition in 2025. Management has emphasized that integration remains a core operational priority, alongside a robust new-product pipeline and continued investment in commercial execution. ([investors.globusmedical.com](https://investors.globusmedical.com/news-events/press-releases?utm_source=openai))
Geographically, Globus derives the majority of its business from the United States, while also maintaining international activity through distributors and non-U.S. commercial channels. Recent disclosures point to solid momentum: the company reported 2025 full-year sales of $2.9389 billion, up 16.7%, with fourth-quarter growth driven by the core spine franchise and enabling technologies. In early 2026, management reiterated its focus on above-market growth, product innovation, and disciplined execution as it works through the integration of its acquisitions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000162828026011124/gmed-ye2025ex991.htm?utm_source=openai))
Overall, Globus Medical can be viewed as a growth-oriented healthcare technology company with a meaningful U.S. spine franchise, expanding procedural breadth, and a strategy centered on innovation, scale, and acquisition integration. ([investors.globusmedical.com](https://www.investors.globusmedical.com/news-events/press-releases?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
